Proto Kinetix, Inc. PKTX
We take great care to ensure that the data presented and summarized in this overview for ProtoKinetix, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PKTX
Top Purchases
Top Sells
About PKTX
ProtoKinetix, Incorporated, a research and development stage bio-technology company, focuses on the scientific medical research of anti-freeze glycoproteins (AFGPs) or anti-aging glycoproteins (AAGPs). The company's AFGPs have commercial applications primarily in health care solutions. It develops AAGP to treat dry-eye diseases. It has a collaboration research agreement with the University of British Columbia. The company was formerly known as RJV Network, Inc. and changed its name to ProtoKinetix, Incorporated in July 2003. ProtoKinetix, Incorporated was incorporated in 1999 and is based in Marietta, Ohio.
Insider Transactions at PKTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 26
2024
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,000,000
+2.77%
|
$0
$0.01 P/Share
|
|
Jun 14
2024
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
3,100,000
+4.35%
|
$0
$0.01 P/Share
|
|
Jun 13
2024
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
3,400,000
+4.96%
|
$0
$0.01 P/Share
|
|
Mar 29
2024
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,500,000
+3.89%
|
$0
$0.01 P/Share
|
|
Mar 20
2024
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
666,667
+1.11%
|
$0
$0.02 P/Share
|
|
Dec 26
2023
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
7,333,334
+11.13%
|
$0
$0.02 P/Share
|
|
Oct 26
2023
|
Michael Richard Guzzetta CFO |
BUY
Open market or private purchase
|
Direct |
20,000
+2.64%
|
$0
$0.02 P/Share
|
|
Aug 29
2023
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
1,500,000
+2.85%
|
$0
$0.02 P/Share
|
|
Jun 15
2023
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,000,000
+3.87%
|
$0
$0.02 P/Share
|
|
May 22
2023
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
3,750,000
+7.29%
|
$0
$0.02 P/Share
|
|
Jan 23
2023
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,000,000
+4.35%
|
$0
$0.02 P/Share
|
|
Dec 30
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
1,850,000
+4.22%
|
$0
$0.02 P/Share
|
|
Dec 21
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Indirect |
100,000
+0.73%
|
$0
$0.03 P/Share
|
|
Dec 16
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Indirect |
65,000
+0.48%
|
$0
$0.03 P/Share
|
|
Dec 15
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Indirect |
78,400
+0.58%
|
$0
$0.03 P/Share
|
|
Dec 14
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Indirect |
94,089
+0.7%
|
$0
$0.02 P/Share
|
|
Dec 13
2022
|
Lachlan Grant Young > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,125,600
-100.0%
|
-
|
|
Dec 08
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,520,000
+5.91%
|
$0
$0.02 P/Share
|
|
Sep 29
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
3,333,333
+8.14%
|
$0
$0.03 P/Share
|
|
Jul 11
2022
|
Clarence Edward Smith President & CEO |
BUY
Open market or private purchase
|
Direct |
2,666,667
+7.22%
|
$0
$0.03 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 19M shares |
|---|